Amendment: SEC Form SC 13G/A filed by Solventum Corporation
$SOLV
Medical/Dental Instruments
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/11/2025 | $80.00 | Hold | Jefferies |
| 7/15/2025 | $103.00 | Equal-Weight → Overweight | Morgan Stanley |
| 7/1/2025 | $90.00 | Hold → Buy | Argus |
| 6/6/2025 | Sector Weight | KeyBanc Capital Markets | |
| 5/19/2025 | $87.00 | Neutral → Overweight | Piper Sandler |
| 12/4/2024 | $70.00 | Neutral | Mizuho |
| 10/8/2024 | $82.00 | Buy | Stifel |
| 10/7/2024 | $71.00 | Neutral | Piper Sandler |
8-K - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
Jefferies initiated coverage of Solventum with a rating of Hold and set a new price target of $80.00
Morgan Stanley upgraded Solventum from Equal-Weight to Overweight and set a new price target of $103.00
Argus upgraded Solventum from Hold to Buy and set a new price target of $90.00
ST. PAUL, Minn., Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the pricing terms of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase for an aggregate purchase price of up to $2.0 billion in cash (the "Aggregate Cap") specified series of its outstanding notes (collectively, the "Notes"). The Tender Offers are being made pursuant to the terms and subject to the conditions set forth in the offer to purchase dated Aug. 22, 2025, as modified by Solventum's prior press release dated Sept. 8, 2025 increasing the Aggregate Cap, the Pool 1 Maximum Amount (as defined below) and the Tender SubCap (as defined below) (the "O
ST. PAUL, Minn., Sept. 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced the early tender results of its previously announced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for an aggregate purchase price of up to an amended $2.0 billion in cash (the "Aggregate Cap"). Solventum has amended the terms of the Tender Offers to (i) increase the Aggregate Cap from $1.75 billion to $2 billion, (ii) increase the previously announced Pool 1 Maximum Amount (as defined below) from $1.25 billion to $1.5 billion and (iii) within the upsized Pool 1 Maximum Amount, incre
Highly Complementary Technologies Strengthen Thermo Fisher's Portfolio in Bioprocessing and Adjacent Markets Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced the completion of its acquisition of the Purification & Filtration business of Solventum (NYSE:SOLV) for approximately $4.0 billion in cash. With the transaction complete, the business, which is now Thermo Fisher's Filtration and Separation business, is part of the Life Sciences Solutions segment. The transaction includes Solventum's Purification & Filtration business serving Bioprocessing Filtration, Healthcare and Industrial Filtration, and Membranes1. The business s
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
Reported sales increased 3.9%; organic sales increased 2.8%Increases full year organic sales growth outlook to +2.0% to +3.0%Increases full year earnings per share outlook to $5.80 to $5.95ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basisGAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69Operating cash flow of $169 million; free cash flow of $59 million"
ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Aug. 7, 2025 Time: 3:30 p.m. CDT / 4:30 p.m. EDT Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (
Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli
BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to
Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza
ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi
SC 13G/A - Solventum Corp (0001964738) (Subject)
SC 13G/A - Solventum Corp (0001964738) (Subject)